{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:27:16Z","timestamp":1761128836617},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,10,29]],"date-time":"2010-10-29T00:00:00Z","timestamp":1288310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We describe a 72\u2010year\u2010old white man with erosive rheumatoid arthritis in whom subacute neurologic and psychiatric symptoms developed after 3 years of treatment with infliximab, prednisone, and methotrexate. White matter demyelination was seen on magnetic resonance imaging of the brain, and progressive multifocal leukoencephalopathy (PML) was ultimately confirmed by brain biopsy. The patient was treated with supportive therapy and discontinuation of disease\u2010modifying antirheumatic drugs, resulting in stabilization of the disease process. The patient survived, but neurologic and cognitive deficits persisted. The distribution and pathology of this patient's disease are unique from almost all reported incidents of oral methotrexate\u2013associated leukoencephalopathy. The pathogenesis of disease may be linked to a T cell\u2013mediated process that is potentially impacted by infliximab. This case provides the first reported evidence that PML can be seen in association with infliximab therapy.<\/jats:p>","DOI":"10.1002\/art.27687","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T03:17:51Z","timestamp":1282187871000},"page":"3191-3195","source":"Crossref","is-referenced-by-count":65,"title":["A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab"],"prefix":"10.1002","volume":"62","author":[{"given":"Deepak","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Bouldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar549"},{"key":"e_1_2_5_3_2","unstructured":"Johnson & Johnson. Remicade becomes first anti\u2010TNF biologic therapy to treat one million patients worldwide. November2007. URL:http:\/\/www.jnj.com\/connect\/NewsArchive\/all\u2010news\u2010archive\/20071106_141812."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0739-z"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0214-9"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0287-5"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01659.x"},{"key":"e_1_2_5_9_2","first-page":"335","article-title":"Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Worthley SG","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308089435"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24906"},{"key":"e_1_2_5_12_2","unstructured":"US Food and Drug Administration. URL:http:\/\/www.fda.gov\/downloads\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/UCM187792.pdf."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.06.029"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.499"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.22.11918-11926.2003"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh215"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.18.10206-10210.2004"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c0d4a1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2721"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0374-4"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27687","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:12:49Z","timestamp":1697044369000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,29]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/art.27687"],"URL":"https:\/\/doi.org\/10.1002\/art.27687","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,29]]}}}